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1. Gene therapy based on adenoviral vectors 
 
1.1. Gene therapy overview 
Gene therapy consists of introducing foreign genetic material into cells of the patient in 
order to treat a specific disease, which can be a genetic disorder or cancer. Genetic 
disease is mainly caused by abnormalities in DNA that yields the loss function of a 
gene, while cancer is induced by mutated oncogenes. A general workflow in gene 
therapy is the following: Identification of affected or missing gene, loading the vector 
with the therapeutic nucleic acid, delivering it into the cytoplasm (and even into the 
nucleus if it is necessary) and performing the therapeutic effect (Jane Flint, Principles 
of Virology, Fourth Edition, 2015). Aiming to treat the different types of complications, 
the new genetic segment can either substitute it with a new functional copy, introduce a 
new gene that can cure the effect of the disease or provide the missing material. 
 
Figure 1. Gene therapy classified according to the source, administration and task. 
However, the gene segment itself cannot survive inside cell on its own because it can 
be digested by enzymes or lysosomes present in cells, so it needs a carrier for its 
delivery and later therapeutic work. The role of carriers or vectors is extremely 
important, since it is responsible not only for carrying the gene to the right cells, but 
also for the gene integration and activation inside the cells. The optimal vector and 
delivery system varies as the target cells, the duration of expression and the length of 
plasmid DNA change too. According to the carriers, the delivery system can be 
classified as viral and non-viral.  
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Non-viral vectors are safer than viral ones in the term that they are not infectious and 
cause less immunological problems. However, the concentration of these carriers is 
also critical since very high amount of foreign substances can be toxic. The non-viral 
gene delivery uses physical methods or chemical carriers. In physical delivery system, 
the cell membrane is perforated or weakened for a while under physical forces and, 
therefore, allow the entrance of the vector-DNA complex, some examples are 
electroporation, hydroporation and mechanical massage. The chemical vectors can be 
classified according to their nature. They can be inorganic, like gold particles or 
calcium phosphate organic, such as lipid based, peptide based or polymer based, 
being the last one increasingly popular (Murali Ramamoorth, 2015). Moreover, they are 
also different in their loading capacity, target cells, ability to integrate the genetic 
material inside the nucleus and remaining period in the cell. Compared with viral 
methods, they have clear advantages in biosafety, but until recent years, they are not 
as intensively researched as viral vectors due to their main limitation: the low efficiency 
at delivering genes into cells.   
Viruses are known by their natural ability of transducing cells by introducing their own 
genetic material and force the cells to synthesize viral components necessary for the 
package and viral proliferation. The eukaryotic viruses are therefore considered as a 
good candidate to deliver the genetic material into human cells. There are a wide range 
of viruses that can be used as gene carrier. For instance, adenovirus, adeno-
associated virus and retroviruses (to which lentivirus belong) are all very well known. 
They considerably differ in the insertion capacity, being adenoviral the one with the 
largest capacity (up to 35kb), and also in transgene expression, compared in Figure 2. 
Even the adenoviral genome is introduced into the nucleus, it is not integrated into the 
host genome, so that the viral DNA will be diluted during cell division and the 
therapeutic effect of the transgene would be transient. In contrast, retrovirus cannot 
carry gene larger than 4.8kb, but its effect is stable because the gene can be 
integrated into the genome of the transduced cells (Lundstrom, 2018).  
 




As during a normal viral infection, the viruses can be toxic spread through a whole 
tissue, they need to be cautiously manipulated before their usage, such that they 
cannot neither replicate nor destroy the host cells.  
Besides the delivery system, the therapy can be performed in vivo or ex vivo. Taking 
the example of hematopoietic stem cells, ex vivo treatment means that the blood cells 
are extracted from the patient, modified by being introducing a foreign gene in vitro, 
and then transplanted back to the patient. In this way, only the extracted and purified 
stem cells are transfected or transduced allowing high specificity and less toxicity in the 
whole organism. In contrast, during in vivo approaches, the vectors are injected into 
the patient, such that the they migrate to the target cells.  
Gene therapy can also be classified depending on how the gene of target cells are 
modified. The addition simply consists of adding a new segment to the gene, while 
gene editing is more complex and leading to DNA double-strand break that need to be 
repaired through homologous recombination (HR) and non-homologous end joining 
(NHEJ), as illustrated in the Figure 3. The first mechanism ensures an accurate repair 
because it uses the homologous template of the complementary strain. NHEJ modifies 
the ends of broken DNA in a random way causing possible deletions and insertions, 
which can be mutagenic, even though its repair is normally accurate and occurs much 
more commonly than HR in the nature. For organisms raised in laboratory conditions, 
HR is the predominant repair mechanism.  
 
Figure 3. After the double-stand breaks, homologous recombination or non-homologous end 
joining could happen, depending on the stimuli provided by the culture environment. 
Gene editing can be performed by meganuclease, Zinc finger, TALEN and CRISPR-





With the development of recombinant technology, gene therapy has become a 
biomedical approach to the genetic disorders because of its ability to introduce a 
therapeutic gene in a vector, which can correct the abnormal DNA sequences of the 
target cells and, thus, to restore the normal production of the specific protein and the 
cellular function. Compared with other non-viral vectors, viral vectors are more efficient 
in editing DNA, although its safety has been considered the main drawback. But during 
the course of time, many researches were performed to reduce the toxicity of these 
vectors.  
Among the main viral vectors, adenovirus is selected as the vector candidate since 
they are not integrative, which means that they do not change the genome of the host 
cells but only make them to produce the proteins of interest. With this property, they 
are appropriate for treatment that requires short-term transgene expression like cancer. 
The adenovirus can carry suicide gene with the goal of tumor cell apoptosis (De-Gui 
Wang, 2016). 
Other features of adenovirus are going to be discussed and taken into account when a 
therapy is being designed. Adenovirus is the largest non-enveloped adenovirus that 
only has an icosahedral nucleocapsid enclosing a double stranded DNA molecule. 
There are five genera of adenoviruses (Atadenovirus, Aviadenovirus, Ichtadenovirus, 
Mastadenovirus and Siadenovirus), among which the Mastadenovirus includes a type 
species called human mastadenovirus C, which are able to transduce human cells. 
Moreover, these human adenoviruses are classified into 57 types and 7 different 
species (from A to G). But the vast variation of adenoviruses, the characteristics of 
serotype 2 (Ad2) and serotype 5 (Ad5) are the mostly studied, being the last one the 
type of vector used in this study. 
 
Figure 4. The genome and protein of adenovirus (Jane Flint, 2015) 
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The genome of adenovirus is about 36 kilobases and it can be divided in two different 
types according to their functions during replication. The regions E1A, E1B, E2, E3 and 
E4 are identified in the first part (Philip Ng, 1999) and illustrated in Figure 4. E1A 
proteins are involved in transcriptional regulation of the virus and stimulate the 
transduced cells to replicate, while the E1B inhibits apoptotic cell signaling. The E2 
region is responsible for proteins necessary during replication, such as DNA-binding 
protein, viral DNA polymerase and terminal protein precursor. The E3 regions encodes 
proteins that evade the host immune system, so its lack does not affect virus growth in 
cell culture. The last region, E4, support the DNA replication by enhancing specific 
gene expression and decreasing host protein synthesis. The genes of the second part, 
numbered from L1 to L5, are expressed after viral replication to produce the viral 
capsid, that encompasses proteins such as fiber, penton base and hexon. The fiber of 
viral capsid binds to the coxsackie virus and adenoviral receptor (CAR) to attach to the 
host cell, then the penton base interacts with v integrin that initiates the endocytosis of 
virus. In addition to these two main viral proteins, there are others being found to play a 
role in adenovirus entry, like heparin sulfate proteoglycan. Once the virus escapes from 
the vesicle, it can reach the nucleus and form the capsid-nuclear pore complex in order 
to introduce the viral DNA into the host nucleus, as illustrated in Figure 5. 
 
 
Figure 5. Adenoviral vector transduction. The adenovirus carrying the transgene enters the cell 
through endocytosis and escapes from the vesicle thanks to penton toxicity. Through capsid-pore 
complex, viral double strand DNA enters into the nucleus and can be expressed without being 
integrated into host-cell DNA (National Library of Medicine (US), 2013). 
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The extensive study about molecular mechanism of adenoviruses' genome and life 
cycle contributes to an easier molecular manipulation of their genome. Moreover, it is 
simple to package the whole genome because only the packaging signal (Ψ) and the 
inverted terminal repeat (ITR) are indispensable, both sketched in Figure 6. This 
implies that a large transgene cassette up to approximately 35kb can be introduced in 
the vector removing the rest of genome, permitting wide range of gene expressions. 
Additional benefits include the reliable virus production methods, high levels of 
expression in both replicating and non-replicating tissues.  
However, there are also some drawbacks that limits their clinical application as vectors. 
A high dose of adenoviruses can be very toxic, because of the spread of viral protein 
and the activation of innate immunity. This was showed in 1999 with the tragedy of a 
patient participating in a clinical trial, during which 3.8x1013 adenovirus particles were 
delivered in an intravascular way through the hepatic artery. This in vivo gene therapy 
was designed to treat partial ornithine transcarbamylase (OTC) deficiency, a metabolic 
disease causing the accumulation of ammonia in the body. The adenoviral vectors 
were “E1-deleted”, E2A-temperature-sensitive carrying the normal OTC gene and 
targeting hepatocytes (Lehrman, 1999). As the administered dose was large, it caused 
first liver dysfunction and then many other organ failures, leading to the death of the 
patient.  
This raised a huge concern about the safety of adenoviral vectors in vivo administration. 
Nowadays, investigators conclude several features that can increase adenoviral 
toxicity. The dose is extremely important, because when there are not enough 
adenoviral receptors in the host cells or tissue, these vectors will migrate to other 
organs, increasing the systemic toxicity. After this failure, the viral vector technologies 
were validated with stricter guideline. The innate immune response is another 
challenge. Serotype 5 adenoviruses are very common viruses in respiratory infection, 
so the patient may be previously infected with these cells and, therefore, deliver the 
specific antibodies. When they are administered again with adenoviral vectors, the 
innate system will quickly respond to it, stimulating a strong reaction.  
In order to minimize the toxicity, a new generation of adenoviral vectors will be used: 












1.3. Helper-dependent adenoviral vectors 
These vectors are manipulated in such a way, that all its viral genes are deleted, 
except the inverted terminal repeats (ITRs) and the packaging signal (Ψ), which are in 
the cis-acting sequences necessary for the vectors to replicate and be packaged. A 
simplified viral genome sketch is found in Figure 6.  
  
 
Figure 6. Serotype 5 adenovirus. A) Wild type Adenovirus. B) First generation vector, with deletion 
of E1 and E3, is replication-deficient. C) HD vector contains no viral gene except the ITR and Ψ.  (Suresh 
K. Mittal, 2011) 
With the deletion of almost all its genes, the vector can carry sequences about 35kb of 
length, which is relatively large and allow a lot of possible combinations. These 
combinations will yield a therapeutic effect in the host cells. In the case where the host 
gene editing is needed, the adenoviral HD vector can carry sequence encoding 
engineering nucleases, such as Transcription activator-like effector-based nuclease 
(TALEN) or (ZFNs) Zinc finger nucleases (Kim YG, 1996). 
Since this generation of vectors cannot produce viral proteins, it depends on a second 







1.4. Helper adenoviral vectors 
The genome of helper virus lacks fragment E1 while it retains the rest sequence 
necessary for growth and to support HD adenovirus packaging. Moreover, the 
packaging signal sequence of helper vector is flanked by two loxP sites. When helper 
viruses assist the HD virus production in 293 Cre4 cells, their packaging signal will be 
deleted. This is the key design to make possible that helper virus is only able to 
ensemble the viral genome of helper-dependent virus and with the presence of 









CRISPR-Cas9 is a new genome editing tool with origin in bacterial adaptive immunity. 
The mechanism of CRISPR, cluster regularly interspaced short palindromic repeats, 
was discovered in 2007 by Barrangou and colleagues. When viruses or plasmids 
invade the bacteria, the foreign DNA is cut into small fragments and integrated into a 
CRISPR locus containing series of short repeats and localized near the Cas9 gene. 
After this locus is transcribed and processed, small RNAs (crRNA) are obtained. Once 
crRNA is associated with tracrRNA, they are able to guide the Cas9 that targets and 
cuts the complementary foreign DNA, as illustrated in Figure 8 A). 
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Basing on this CRISPR system, the trRNA and crRNA could be combined into a single 
guide RNA (sgRNA), as in Figure 8 B), in 2012 by Doudna and Charpentier labs(Jinek 
M, 2012). Compared with other engineered nucleases mentioned before, such as 
TALENs and ZFNs, Cas9 is simple to use because it does not need to generate a new 
nuclease pair for targeting each new sequence, which is a difficult and time-consuming 
process. By only reprogramming the two guide RNA, it can target any sequence.   
 
Figure 8. A) Cas9 activity in bacteria. Cas9 form a complex with both crRNA and tracrRNA in order to 
perform a site-specific DNA recognition and cleavage (Alex Reis, 2014). B) Engineered Cas9 activity. 
Once the Cas9 recognizes the PAM in the host cell and the sg RNA is complementary to it, cleavage will 
be proceeded. 
 
This complex protein is mainly composed of two lobes, leaving a space to hold sgRNA 
between them during activation. In one of the lobe, the nuclease domains that actually 
break the DNA are found. They are RuvCs, HNH and CTD domains, being the last one 
containing sequence that will interact with the Protospacer Adjacent Motif (PAM). It 
should be recall that PAM and sgRNA are the ribonucleotides, such that they need to 
be recognized by the protein lobes at specific site to form the ribonucleoprotein.  
Once the Cas9 complex becomes in contact to the DNA, it tries to target the sequence 
of interest. For that, it uses the PAM sequence to perform the first search. Once it finds 
the PAM, it denatures part of DNA and enables the base pairing of sgRNA and DNA. If  
they are totally complementary to each other, the DNA cleavage occurs. The wild-type 
Cas9 is able to create this DSB break, activating the repair mechanism that can be 
homology-directed repair (HDR) or non-homologous end joining (NHEJ), as illustrated 
in Figure 9 B). The problem of some types of Cas9 is that, a base mismatch can be 
tolerated, so that even they did not match perfectly, the protein can cut at wrong sites, 




2. The skin 
The structure of skin is important for a better understanding of the skin rare disease 
and the designed gene-editing correction. It consists of three layers, which are, from 
outermost to the innermost one, epidermis, dermis and hypodermis. Each of them is 
composed of different cells and proteins and performs a specific function.  
 
2.1. Epidermis and basement membrane 
It is epithelial tissue and is mainly compsed of keratinocytes, that derive from the basal 
layer (with cubical form) and migrate to the corneal layer (with squamous form), as 
illustrated in Figure 9. In this way, they are constantly being renewed. Between the 
corneal and basal layers, there are two more layers of cells between them. Beneath, 
there is a thin layer that connects it to the dermis, the dermal-epidermal junction (DEJ), 
a basement membrane. As any basement membrane, it consists of layers of 
extracellular matrix which are the basal lamina (lamina lucida and lamina densa) and 
the lamina reticularis, hold by attaching proteins such as collagen VII and fibrillin.  
 
Figure 9. Main proteins in the epidermis with structural function (Lee, 2013). 
In the dermoepidermal junction (DEJ), Collagen VII plays a crucial role because it 
attaches the lamina densa to the papillary dermis. Its malfunction or deficiency can 
lead to the separation of epidermis from the dermis even after a smooth rush, such that 




Rested beneath the DEJ, dermis is connective tissue that supports the epithelial tissue 
(epidermis) by providing the blood vessel, nerve and lymphatic vessels necessary for 
the proliferation and growth of keratinocytes.  
It differs from the epidermis not only in the function because of different cell types and 
chemical compositions. In the upper tissue, the major cell type is keratinocyte, while in 
the lower tissue, it is fibroblast. This also induces the second difference: chemical 
composition. The epidermis hardly contains extracellular matrix except in the basement 
membrane, but the dermis is filled of extracellular matrix, synthesized by the fibroblasts.  
Dermis also contains three layers, which are the papillary layer, the subpapillary layer 








It is the subcutaneous fat tissue that stores neutral fat and water, and that provides 
pressure resistance. The dermis is hold firmly to this deeper layer by fiber bundles 





3. Dystrophic epidermolysis bullosa (DEB) 
The dystrophic form of epidermolysis bullosa is a heritable skin disease characterized 
by abnormal blistering of the skin. This blistering can also occur on the mucous 
membrane and sensitive part like in the eyes. Depending on the phenotypes, it is 
classified in many groups, being the mildest phenotype the nail-only dominant DEB 
phenotype, while the most severe one is the severe generalized recessive DEB 
(RDEB). The last one can lead to large area of blistering and scarring causing the 
fusion of fingers and toes. But the deadly consequence of this phenotype is the 
development of squamous cell carcinoma, that occurs with a very high possibility. 
From the genetic point of view, it is caused by mutation in the gene encoding the pro-
alpha1 chain of type VII collagen (COL7A). This mutation can be inherited, being 
autosomal dominant or recessive. In order to understand how a mutation affects these 
proteins, we should first know the sequence at DNA level, then the resulting protein 
structure and function. 
3.1. Collagen VII structure 
The collagen type VII is the main protein of fibrils that tightly hold the epidermal 
basement membrane to the dermal layer. The mRNA of this gene consists of 8832 
base pairs and contains 118 exons of short length that encode a polypeptide of 2944 
amino acids. But the whole gene is about 31 kb on chromosome level. The gene 
contains a central domain made of Gly-X-Y repeat. This repeat, with a total length of 
145 kD (approximately 220 bp), is responsible for the triplet helix formation and 
mechanical strength of the protein, but it is interrupted by 19 non-collagenous regions 
that provide flexibility to the long chain. There are some other non-collagenous 
domains that are important for collagen VII maturation and fibril formation. Every three 
chains of pro-alpha 1 twist to form procollagen helix molecules inside cells, as 
illustrated in Figure 11. Once they are secreted from the cells, they are processed and 
fold into a long mature collagen. Two Collagen VII monomers bind to each other in an 
antiparallel way and overlap in their carboxyl termini stabilizing disulfide bridges. Finally, 
to form the fibrils that tightly anchor the epidermal layer to the dermal one, lots 
antiparallel dimers stack together forming a single fibril. 
 
Figure 11. Collagen VII fibril assembly (Christelle Bonod-Bidaud, 2013) 
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3.2. Mutations in collagen VII coding gene 
The genotype-phenotype correlation from a study (Peter C. van den Akker, 2011) 
shows that mutations, such as frame-shifting deletions or insertion, are the main cause 
of DEB. After the point of frame-shifting mutation, the reading frame shifts in such a 
way that the codons (each codon contains three bases) change completely and a 
premature stop codon can appear in DNA sequence or transcribed mRNA, resulting in 
a truncated and nonfunctional collagen product. The mutation leading a shorter 
transcript is called premature termination codon (PTC) mutation. This mutation can 
occur in one or both alleles. In mild DEB, there is normaly only one mutated allele, so 
that the amount of fibrils are reduced. In severe generalized DEB patients, the 
anchoring fibrils are absent in the skin because both alleles are mutated.  
 
 
Figure 12. Insertion of Cytosine base at position 6527 causing frameshift mutation and yielding a 
different amino acids chain with shorter length (W.Pelley, 2012) 
 
 
Figure 13. Simplified scheme of recessive dystrophic epidermolysis bullosa (Michael Vanden Oever, 
2017).  
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3.3. Strategies for EB treatment 
Many strategies have been designed in order to recover adhesion between dermis and 
epidermis through the recovery of the protein. Cellular therapy is one of the 
approaches. A good example is the European clinical trial based on the intravenous 
injection of normal mesenchymal stem cells (MSCs) collected from one of the parents 
of the RDEB patient (EudraCT Number: 2017-000606-37). It was showed that the 
MSCs extracted from bone marrow of a genetically similar healthy person were able to 
improve the COL7A1 expression in the dermal-epidermal junction. 
As the origin of the disease is caused by mutation, genetic therapy could restore the 
normal expression of the disease-causing gene for a longer period of time, without the 
need of several administrations. As illustrated in Figure 1, there is a high variety of 
methods. The non-viral approaches mainly use polymers or lipids to deliver the full 
length COL7A1 (addition) (Cutlar L, 2016) or the gene encoding an engineered 
nuclease (gene editing).  
Among the viral therapy, the lentivirus was firstly used to perform COL7A1 gene 
delivery. Then retrovirus containing full-length COL7A1 gene was able to transduce 
fibroblasts and correct the gene, thus corrected skin equivalent can be created and 
transplanted to RDEB patient. This autologous graft was tolerated during one year with 
collagen VII production (Georgiadis C, 2016; Georgiadis C, 2016).  
Furthermore, the regeneration of the whole epidermis derived from corrected stem 
cells was achieved in a patient suffering junctional epidermolysis bullosa (JEB), 
another genetic skin disease characterized by the lack of laminin-332 in the basement 
membrane. The primary keratinocytes cultures were established from a small biopsy of 
a non-blistering area. After transduction with retroviral vectors expressing the laminin-
332 gene, the transduced keratinocytes were cultured and expanded into epidermal 
grafts thanks to the presence of transgenic epidermal stem cells.  Then they were 
transplanted on the dermal wound bed of the patient. Adhesion between the epidermis 
and dermis was still observed after 21 months of transplantation while no blister was 
formed in the regenerated epidermis (Tobias Hirsch, 2017). This approach is an ex 
vivo gene addition therapy approach.  
All these advances strongly encouraged further gene therapy studies focused on 
genetic skin diseases. 
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MOTIVATION AND OBJECTIVES 
 
Gene therapy is one of the most compromising treatment of a vast number of genetic 
disorders, that could not be treated with proper methods decades ago. With the 
technological advance and extensive basic researches, many of these diseases have 
been reported to be cured with gene therapy. Severe combined immune deficiency, 
hemophilia and leukemia are now target of clinical trials of this therapy. Furthermore, 
patient suffering metabolic disorders, neural diseases, and even cancer are now being 
treated with different kind of vectors. The gene modification is a such complex process 
that involves the entrance of vectors into the host cells, the delivery and expression of 
the genetic information that serves as a therapeutic purpose. The strategy strongly 
depends on the target cells and the type of vector used, such that every approach is 
specific and unique.  
For epidermolysis bullosa, such as RDEB and JEB, long-term skin regeneration based 
on ex vivo gene addition therapy has been achieved with great results in the research 
center CIEMAT, but some problems were stated in this kind of therapy. The viral gene 
delivery efficiency is still low; the expression of the gene of interest cannot be 
accurately regulated to occur in the desired place and time; and the risk of insertional 
mutagenesis due to the usage of integrative viral vectors. Hence, gene correction was 
considered as a more precise alternative, in which the engineered nucleases perform 
site-specific cleavage in the mutated gene.  
In a previous study (Cristina Chamorro, 2016), first-generation adenoviral vectors were 
used for correction of RDEB based on HDR and NHEJ. In Spain, the insertion of 
Cytosine base at positon 6527, within exon 80, (mutation c.6527insC) causes a 
recurrent frameshift mutation in 46% of recessive DEB alleles. Due to this high 
prevalence, the gene editing was focused on the exon 80. It showed that the deletion 
of exon 80 by using TALENS, delivered by adenoviral vectors, could restore the correct 
reading frame and subsequently, the collagen VII normal function in the adhesion 
between epidermis and dermis of skin.  
The design and production of TALENS is tricky and time-consuming because the 
nucleases need to be modified according to the sequence of interest. For a generalized 
gene editing to treat many other mutations causing DEB, CRISPR-Cas9 system is 
considered a better tool. For this purpose, several dual sgRNA were tested to choose 
the sgRNA pair that results in the highest exon 80 deletion percentage. The 
ribonucleoprotein complex (sgRNA-Cas9) was delivered into the primary keratinocytes 
through nucleofection and was found to restore the reading frame of COL7A1 in a large 
proportion of cells, which consequently synthesize functional collagen VII variant (Jose 
Bonafont, 2019). 
Back to the delivery system for sgRNA-Cas9 complex, adenoviral vectors have been 
chosen because of their ability to infect quiescent cells like stem cells. But the first-
generation is limited for in vivo application due to the relatively high toxicity due to the 
viral genome remaining in the host cells.  
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Therefore, this study aims at generating a less toxic version of adenoviral vector 
carrying a gene encoding sgRNA-Cas9 that can delete the specific exon and, in this 
manner, correct the collagen VII expression, as illustrated in Figure 14. For this 
purpose, simple 2D cultures are assessed in term of infection while more complex 3D 
cultures mimicking in vivo gene therapy are evaluated in DNA level to confirm the gene 
editing through NHEJ, following the workflow indicated in Figure 15. 
 
Figure 14. HD adenovirus serves as the delivery system of gene encoding sgRNA-Cas9 into the 




Figure 15. Simple workflow of the project. 
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MATERIALS AND METHODS 
 
1. Patient primary cells acquisition  
With informed consent and approval of the Hospital Ethics Committee, the human 
keratinocytes and fibroblasts with c.6527insC mutation in the exon 80 of gene COL7A1 
were extracted from a RDEB patient. After several cycles of mechanical disintegration 
and enzymatic digestion of the skin biopsies, the cells were extracted and cultured in 
conditions different for keratinocytes and fibroblasts or 293 Cre4 cells. 
 
2. Culture of different cell types  
All cellular cultures were maintained under a humid environment with 5% CO2 
concentration in an incubator (NAPCO) at 37ºC. To ensure a sterile condition, 
experimental work with cells was performed in laminar flow hood of biosecurity level II 
(BioUltra, Telstar).  
 
2.1. Keratinocytes 
In normal physiological condition, keratinocytes rest on the layer formed by fibroblasts, 
which provide nutrients and signals through extracellular matrix to support the epithelial 
cells proliferation and differentiation. Nevertheless, the presence of fibroblasts makes 
the DNA analysis difficult, so alternatives to these cells, like feeder layer, were used. 
Feeder layer cells were modified in a way that they cannot divide, but still were able to 
provide extracellular secretions and support the proliferation of a single cell type culture. 
Depending on the type of target cells, feeder layer cells could be different, and for 
human keratinocytes, 3T3 cells could be used after being irradiated with a 50 Gy dose 
of X-Rays. 
 
Keratinocytes seeding medium is used to promote cellular adhesion and consists of: 
- 150 mL Dulbecco's Modified Eagle Medium (DMEM, GlutaMAX, Gibco) 
- 75 mL of HAM’s F-12 (F-12 Nutrient Mix, GlutaMAX, Gibco)) 2:1 proportion with 
DMEM 
- 10% bovine calf serum (HyCloneTM) 
- adenine (2.43 ng/mL, Sigma) 
- cholera toxin (0.1 nM, Sigma) 
- epidermal growth factor (10 ng/mL, Sigma) 
- insulin (5 μg/mL, Sigma) 
- Triiodothyronine (0.2 ng/mL, Sigma) 
- antibiotics  
 
After 48 h of incubation, seeding medium was replaced by the keratinocytes growth 
medium, which contains the same components as seeding medium but supplemented 
with 10 ng/mL epidermal growth factor (EGF, Sigma). This medium was renewed every 
48-72 h.  
When the culture reached a 90% confluency, subculture was proceeded. 
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The medium was removed firstly, followed by washing with Phosphate Buffer Saline 
(PBS, Sigma) and addition of trypsin for cell detachment. 20 minutes of incubation at 
37ºC was needed to detach the keratinocytes. Once the cell detachment is confirmed 
through microscopic observation, trypsin is inhibited to avoid further digestion by 
adding DMEM.  
 
2.2. Fibroblasts 
Compared with keratinocytes, fibroblasts are more independent from other cell 
types. Moreover, medium used for seeding and maintenance has the same 
composition: 
- DMEM 
- 10% Fetal Bovine Serum (FBS, HyCloneTM)  
- 1% antibiotics 
For the subculture, trypsinization was proceeded, but fewer time was needed for 
fibroblasts detachment. 
 
2.3. 293Cre4 cells 
293 Cre4 cells are human embryonic kidney epithelial cells immortalized in laboratory. 
These cells were firstly obtained by being transduced with sheared adenovirus 
serotype 5 and, later they were selected because they could be maintained for several 
months. When the cells gradually adapted to tissue culture, they become a stable HEK 
cell line.  
293 Cre4 cells are used in the propagation of adenoviral vectors since they play great 
role in the Cre/loxP method developed by Graham and co-workers (Chen L, 1996). Cre 
is a site-specific recombinase that acts on a target sequence called loxP. The pair of 
sequence loxP is found in the Helper virus genome, such that once the Helper vectors 
are cultured with 293 Cre4 cells, their DNA molecule will be cut at the Cre recombinase 
at sites of loxP, splitting into two fragments that cannot be packaged later, illustrated in 
Figure 7. This serves as a second restriction to avoid Helper virus from assembling 
their own genetic information and producing toxic viral protein.  
Cryo-preserved 293 Cre4 cells were thawed in warm bath at 37ºC. They were counted 
before plating them and the concentration was calculated. To achieve a uniform 
distribution of cells, the dishes were covered firstly with culture medium, followed by 
the cell delivery. 
As in the case of fibroblasts, the medium used for 293Cre4 cells seeding and 
maintenance has the same composition: 
- DMEM 
- 10% Fetal Bovine Serum (FBS, HyCloneTM)  





3. Helper-Dependent adenoviral vector DNA construction 
The generation of HD adenoviral vectors was based on the pC4HSU plasmid, that 
includes the adenoviral sequences necessary for vector DNA replication (Inverted 
Terminal Repeats, ITRs) and packaging, as well as non-coding human genomic DNA 
(stuffer DNA necessary to reach a minimum vector size). pC4HSU was digested with 
AscI and NotI restriction sites and ligated to a 6.3 kb BssII/ NotI fragment containing all 
the sgRNA-Cas9 system elements. This fragment was obtained from plasmid dg-PGK-
SaCas9-iGFP, previously generated in the same laboratory for generation of first 
generation adenoviral vectors and includes a Cas9 and GFP expression cassette as 
well as two cassettes for expression of sgRNAs designed for generation of DNA breaks 
at sequences flanking COL7A1 exon 80. The resulting plasmid, in which 4 kb of stuffer 
was replaced with the sgRNA-Cas9 elements, had a size of 37 kb, and was used for 
generation of the HD vectors.       
 
  
Figure 16. A) Transgene introduced into pC4HSU to express the sgRNA-Cas9 with two sgRNA and 
also to express GFP following a iRES. B) The two sgRNA target the fragments flancking the exon 80 and 
allow deletion by Cas9 at the site marked with blue arrows. 
 
The PGK promoter drives Cas9 expression in all cell types, allowing the removal of 
DNA following the direction of guide RNAs. The Cas9 (CRISPR associated protein 9) 
used is a nuclease isolated from bacteria Staphylococcus Aureus, because this 
species of bacteria provides a Cas9 with a smaller size, such that it could be packaged 
into viral vectors more easily than other Cas9 variants derived from bacteria, such as 
the widely used Cas9 from Streptococcus pyogenes. Moreover, S. aureus Cas9 is 
more specific in term of PAM requirement (S aureus PAM is more complex and less 
frequent in the human genome than S pyogenes PAM), minimizing possible wrong 
targeting.  
SgRNA (single guide RNA) 12835 and 12892 carried by the transgene are small RNAs, 
complementary to two DNA sequences of 20 bp flanking the fragment to be deleted 
(COL7A1 exon 80). The numbers 12835 and 12892 specify the position of the guide 
RNAs and correspond to numbers in a DNA fragment that contains the COL7A1 gene. 
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IRES is an RNA sequence that initiates the translation of GFP downstream sgRNA-
Cas9. In this way, Cas9 and GFP are co-expressed and therefore the cells expressing 
sgRNA-Cas9 are detectable by fluorescence microscopy. The PAM sequence 
(Protospacer Adjacent Motif) is the genomic sequence immediately adjacent to the 
sequence complementary to the guide RNAs and its presence is necessary forCas9 
RNPs functionality. 
Plasmid subcloning for generation of the final HD construct was done using XLBLUE 
competent cells. For each subcloning step, miniprep plasmid DNA was analyzed by 
restriction analysis to check the construct content.  
 
4. HD adenoviral vectors production 
 
4.1. Viruses preparation for the transfection 
One day before transfection, HD vector was linearized by digesting 5 µg of plasmid 
with PmeI restriction enzyme for 2 hours and then heating to 65ºC for 20 minutes. Then 
it was purified by Phenol/Choloroform extraction and ethanol precipitation and after 
resuspension in TE (Tris-EDTA) buffer it was stored at 4ºC for the transfection. One 
hour prior to transfection, the culture medium was replaced by freshly prepared 
medium without washing.  
To set up the transfection reaction, herring sperm DNA at a concentration 1100μg/mL 
was added to 1mL of HBS (HEPES-Buffered Saline) buffer in a polystyrene tube. The 
solution was vortexed for 1 minute at maximum setting. Then the HD vector plasmids 
was added to the tube and mixed gently. 25μL of 2.5M CaCl2 were added dropwise 
with mixing and the whole solution was incubated at room temperature for 30 minutes. 
 
4.2. 293 Cre4 cells transfection 
0.5 mL of the prepared solution was applied dropwise to the monolayer of 293Cre4 
cells and the dish was rocked to distribute the precipitate uniformly. Then overnight 
incubation proceeded.  
The next day, the medium was removed from the transfected monolayer (with HD 
vectors), that was later washed with DMEM and then immediately transduced with 
helper virus at a multiplicity of transduction (MOI) of 5 pfu/cells. There were 3x106 cells 
in the dish to be transduced, so we needed 3 μL of Helper virus with concentration of 
109 particles/200 μL to achieve MOI of 5 pfu/cells. The Helper virus was adsorbed for 
one hour in the incubator with rocking every 10-15 minutes. Then 5 mL of DMEM was 
added to the monolayer. 
Complete cytopathic effect (CPE), which means more than 90% of the cells are 
rounded up and detached from the dish, was observed by about 48 hours post-
transduction. At this time, the cells were scraped into the medium and the whole cell 
suspension was transferred into a polypropylene tube and then stored at -70ºC after 
the addition of 10% volume (around 5mL) of 40% sucrose.  
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4.3. Serial passages 
The frozen first passage lysate was thawed at 37ºC, at which condition the 298 Cre4 
cells break, and 0.4 mL of lysate was taken to transduce a 60-mm dish of 90% 
confluent producer cells at MOI of 1 pfu/cell, then the monolayer was transduced with 
0.4 mL of helper virus. The dish was returned to the incubator for one hour of 
adsorption, followed by the addition of 5 mL maintenance medium. 
After observing complete cytopathic effect through microscope 48 hours after 
transduction, the cells were resuspended in the medium by scraping them, and 
transferred to a new polypropylene tube. This second passage of the vector was again 
stored at -70ºC after the addition of 0.5 mL of 40% sucrose. 
 






After seven serial passages, the latest passage was chosen for large-scale preparation 
of HD vector. 
Twenty dishes of 150 mm diameter were seeded with 0.5 million of 293Cre4 cells each. 
One week later, when 90% confluency of the producer cells was observed, 1 mL of 
Helper Dependent vectors and 1 mL of Helper vectors were added to each dish to 
coinfect the cells at a MOI of 1 particle/cell. The dishes were rocked every 10 to 15 
minutes in order to ensure uniform interaction of vectors with the cells and were placed 
in incubator for one hour, process completed with the addition of 15 mL of DMEM to 
each dish. 
Complete CPE was observed 48 hours post-transduction, so the cells were scraped 
into the medium and the cell suspension was collected for extraction purification of the 
HD vector.  
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5. HD adenoviral vectors purification 
 
5.1. HD vector extraction  
The harvested cells and medium underwent centrifugation. The supernatant was 
discarded and the cell pellet was resuspended. Then it was centrifuged again at 4000 
rpm for 10 minutes to separate the cellular and viral components. This time the 
supernatant was collected while the pellet containing cellular debris was discarded. 
 
5.2. CsCl step gradient preparation 
CsCl centrifugation, used for density-based separation, is a process in which the 
molecules to be separated are mixed with CsCl and centrifuged at very high speeds 
overnight. The gradient consisted of overlays of CsCl of different concentrations. 0.5 
mL of 1.5g/mL CsCl solution was firstly added, then 3 mL of 1.35 g/mL solution was 
overlaid, following by overlaying 3 mL of 1.25 g/mL solution. Then 5 mL of supernatant 
containing the viral vectors was applied to the top of the gradient. Finally, the tubes 
were topped up with 100mM Tris-HCl. 
 
5.3. CsCl centrifugation 
The tubes were spun at 35000 rpm overnight. The centrifugal force caused the 
components of the mixture to separate by size and gradually pushes the components 
with higher density toward the bottom of the tube. The centrifuged solution contained 
several bands corresponding to viral vectors separated by density, being the band at 
the bottom denser than the band at the top. The genome of Helper vectors is slightly 
larger than that of HD vectors, and therefor the bottom band corresponds to the Helper 
and the top band to the HD vector. 
The top band was collected with needle and syringe by piercing the side of the tube, 
taking as much of the band as possible. Then it was transferred to Slide-A-Lyzer 
dialysis cassettes that had been previously submerged in distilled water to remove the 
glycerol. Then the cassettes were submerged into 500 mL 10mM Tris-HCl and spun 
overnight, with two changes of the same solution. In this way, the salts of CsCl were 
removed from the vectors. 
 
Figure 18. Viral band obtained after CsCl ultracentrifugation. 
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The titer of the viral vector preparations was determined by spectrophotometry. The 
concentration of viral vectors is directly proportional to the concentration of viral 
genomic DNA. The purified virus particles were diluted 20-fold with Tris-HCl/0.1%SDS 
buffer. Then the virus sample was measured at A260 with the NanoDrop and the 
concentration is calculated by using the following formula:  
OD260 × Dilution Factor × 1.1 × 1012 ×
36
𝑉𝑒𝑐𝑡𝑜𝑟 𝑆𝑖𝑧𝑒
    
 
 
6. 2D culture preparation and transduction 
 
After reaching 90% confluency, they were infected with HD adenoviral vectors at 
different MOI. 
6 days after infection, the cultures were observed through fluorescence and brightfield 
microscopy, while images were acquired for analysis. 
 
Both the brightfield and fluorescence microscopy images were obtained 6 days after 
the transduction. Due to the different texture, brightfield images were processed by 
following part of a protocol (Čepa, 2018), while the fluorescence images were 
processed in a different method. To begin with, they had to be converted into 8-bit 
grayscale images. 
1. Brightfield image enhancement through histogram equalization: run (“Enhance 
Contrast…”, “Saturated=0.3%”, “equalize”) 
2. Canny edge detection with Gaussian Kernel: run ("Canny Edge Detector plugin”, 
“Radius=1”, “Low threshold=4”, “High threshold 7.5”, “Normalized contrast”) 
4. Closing, a morphological operator that fills the remained small holes 
5. Dilation, another morphological operator that expands the shapes after closing 
 
For the fluorescence images, due to their smooth texture, the processing steps simply 
consisted of thresholding with a range of 23 to 255 intensity, followed by dilation.  
Now, the image contained maximum value in the background (white) and minimum 
value in the positions representing the cells. Area fraction (Analyze>set measurement) 
was used to assess the confluency percentage and the percentage of transduced cells 
(with respect to the whole image). The percentage of transduction with respect to the 









7. 3D culture preparation and transduction 
 
7.1. Skin equivalent preparation 
This culture system mainly consisted of two cellular components: keratinocytes and 
fibroblasts, maintained in differentiation medium and fibrinogen respectively. The 
keratinocytes were the same used in 2D culture, while the fibrinogen was obtained 
from pig blood plasm in the form of cryoprecipitate. Fibrinogen was found in liquid state 
at room temperature but it would form gel in the presence of thrombin, which in turn, 
would need calcium to be activated. Calcium had its origin in CaCl2 solution. Another 
detail of the mixture was the addition of tranexamic acid that avoided the degradation 
of fibrin by fibrinolytic enzymes called plasmin. In the lab, the plasma was not viscous 
on its own, but when it was in contact with fibroblasts, these cells speeded up the 
gelling process of plasma due to the presence of proteins involved in pre-inflammatory 
condition. 
The key step during fibroblasts seeding was to achieve a homogenous distribution of 
these cells within fibrinogen solution and to prevent the gel formation inside pipettes 
that makes the seeding difficult. For this purpose, fibroblasts suspended in human 
keratinocytes medium were mixed with tranexamic acid, proteinase and thrombin 
solution while the cryoprecipitate component was introduced in the last moment to 
complete the mixture. The manipulation was fast to avoid gel formation inside the 
pipette.  
In each well, there was a mixture of 3.5 mL containing the following: 
- 100K fibroblasts resuspended in human keratinocyte medium 
- 60 µL of tranexamic acid 
- 500µL of a 0.025mM CaCl2 (Sigma Aldrich) dilution in which11 IU of thrombin 
(Sigma Aldrich) is found 
- 1mL of blood cryoprecipitate (fibrinogen) 
Two different plates were used and later incubated at 37ºC in a 5% CO2 atmosphere to 
allow the fibrin gel formation. The first one contains transwells, the function of which 
was to allow the air-liquid interface, the main mechanism of keratinocytes 
differentiation in vitro. The other plate with normal wells would be used for engraftment 
on mice. 
Once the fibrin gel was formed, primary keratinocytes were thawed in warm bath, and 
then resuspended in the differentiation cocktail described in section 2.1., but with 1% 
bovine calf serum instead of 10% and ascorbic acid (50 µg/mL). 
To the two organotypic culture plates where the blister would be created artificially ( in 
vitro) and to one plate of culture prepared for transplant (in vivo), 5x105 normal 






7.2. Keratinocytes differentiation 
 
7.2.A. In vitro differentiation and maturation 
 
Figure 19. In vitro differentiation of keratinocytes due to the air-liquid interphase and 
differentiation medium. 
 
The differentiation was stimulated by the change in the composition of the culture 
medium and also by the air-liquid interface that assembled to the real biological 
environment of skin. The outermost layer of skin was always exposed to air while the 
basal part rest on the dermis. Therefore, in order to differentiate the keratinocytes into 
squamous stratified tissue, the basal part of these cells had to be in contact with the 
medium. In this way, the keratinocytes proliferated, gradually left the medium and 
became in contact with the air, in a way that they differentiated following this gradient. 
At the same time, the dermal layer was always immersed in maintenance medium. This 
was the most commonly used approach for in vitro 3D skin model and the whole 
process of differentiation of keratinocytes and epithelium formation takes 20 days. 
 
7.2.B. In vivo differentiation and maturation 
Once the seeded keratinocytes reached confluency and completely attached to the 
fibrin matrix, the whole structure was separated from the culture plate for 
transplantation on immunodeficient mice. According to the methodology described in 
(MARCELA DEL RIO, 2002), a 20-mm circular partial-thickness fragment (containing 
epidermal and dermal layers) on the mice dorsum was removed from the skin and 
underwent devitalization through three repeated cycles of freezing and thawing. This 
process turned this removed piece of skin into a biological bandage that, after being 








7.3. Blister formation and adenoviral vectors injection 
Blisters were created on organotypic cultures to mimic epidermal-dermal detachment in 
RDEB and allow the evaluation of different viral vectors to deliver gene-correcting 
molecular tools. This assessment was performed both in vitro and in vivo conditions. 
 
7.3.A. In vitro condition 
After 7 days of differentiation through air-liquid interface in vitro, the epidermal layer 
acquired different properties and phenotype than dermal layer, such that two layers 
could be easily identified after one week of incubation. This difference facilitated the 
whole process. The blister was formed by using a syringe with needle. Firstly, the 
needle was inserted beneath the upper layer, then air was injected separating a little bit 
the two layers.            
 
7.3.B. In vivo condition 
Compared with in vitro differentiation, in vivo condition provided a better environment 
for the organotypic culture to mature and become more similar to natural skin tissues. 
As this regenerated skin was tightly attached to the mouse hypodermis and the 
different layers could not be distinguished, the method used in the in vitro section was 
not suitable. An alternative needed to be used for blister formation. 
The mouse was anesthetized and prepared for manipulation. The first step was to 
check the autofluorescence of normal living cells in order to obtain a reference image 
allowing later observation of fluorescence emitted by the transduced cells. The area of 
graft was then marked for easier visualization during the whole process. The second 
step consisted of the device setup. The cylindrical plastic chamber was placed on its 
dorsum, in such a way that the human skin graft just matched the hole of the chamber. 
The chamber was connected to the vacuum generator. Once the pressure supply was 
turned on, the compressed air was accelerated and generated a suction effect. The 
appropriate pressure range spanned from 10inHg to 13inHg (254 to 330.2mmHg). The 
skin should be carefully stretched, so that only the graft was under suction, otherwise 
the blister would not form between the epidermis and dermis. 
After obtaining the blister, the aliquots of adenoviral vectors were firstly mixed with 
30mL of Matrigel, and then injected inside the blistered graft. The Matrigel solution, 
containing mainly laminin and collagen, prevented viral suspension from leaking out 
from the blister. In this way, fibroblasts and keratinocytes could be infected with as 
many viral particles as possible. Finally, the light from the device promoted the polymer 







8. DNA extraction, amplification and analysis 
 
8.1. DNA extraction 
Keratinocytes or fibroblasts maintained in 2D culture were collected and centrifuged to 
remove the medium. Then, they were distributed to different 1.5 mL tubes, according to 
the MOI, to be processed. However, in 3D culture, the epidermal and dermal layers 
must be separated and processed in two tubes respectively for each MOI.  
The following tissue digestion protocol was common for both culture systems. The first 
step was the addition 700 µL of lysis buffer with the following components:  
- 20 µL of 50mM Tris-ClH (pH 8)  
- 80 µL of 100mM EDTA (pH 8)  
- 8µL of 100mM NaCl  
- 40 µL of 1% SDS 
Then 18 µL of proteinase K (20mg/mL) was added to digest the proteins. 
After overnight incubation at 55ºC at 650 rpm, 4 µL of RNAase A+T1 was added 
and followed by 30 minutes incubation at room temperature. Then 250µL of saturated 
NaCl was added and the tubes were shaken for 10 minutes without using vortex. After 
5 minutes of centrifugation at 14K rpm, 850 µL of supernatant containing DNA was 
collected to another tube. 500 µL of cold Isopropanol was used to precipitate DNA 
molecules when the tubes were being smoothly shaken for 5 minutes, followed by 5 
minutes of centrifugation at 12000 rpm. After removing isopropanol, 500 µL of 
80%ethanol was applied to wash the pellet for 3 minutes of centrifugation at 12000 rpm. 
Ethanol was removed as much as possible but ensuring intact DNA pellet. Finally, DNA 




8.2. Polymerase Chain Reaction 
The concentration (ng/µL) of extracted DNA was confirmed by using 
spectrophotometer (ND-1000, NanoDrop), and PCR genotyping was performed in the 
following conditions 
- 1.5 µL of 10x Buffer  
- 1.5 µL of MgCl2 (25mM) 
- 2 µL of dNTPS (10mM) 
- 1 µL of primer targeting COL7A R [10] (5’ -ACCCCACCAAGGAAACTGA-) 
(10mM)  
- 1 µL of primer targeting COL7A F1 [10] (5’ -GTGAGTGGTGGCTGAAGCAC-) 
(10mM)  
- 6.35 µL distilled water  













1 1 96 300 
2 5 96 30 
  65 30 
  72 30 
3 30 96 30 
  60 30 
 
 
8.3. Agarose electrophoresis gel 
The fragment amplified by PCR contained the intron 79 and exon 80 while the segment 
removed by Cas9 consisted of exon 80 and some adjacent base pairs, such that a total 
deletion of 57bp was expected. In order to visualize the deletion of this small segment, 
1.5% (1.5 g/100mL solvent) of agarose gel was prepared. (Technology for Genetic 
Analysis, 2012). 
First of all, low EEO agarose powder (CONDA) was weighted and dissolved in 
corresponding volume of 10X TAE or TBE 1X, after being boiled and shaken. The 
bottle was cooled a little bit and ethidium bromide was added with 0.005% (volume) to 
interact with DNA and to make it visible under UV light. Then it was poured into the 
plate mold and the wells were created by inserting a comb into the slots, and let it 
solidify at room temperature. Once the gel was totally solid, it was placed in the 
electrophoresis box.  The chamber was filled with the same solution in which the gel 
was made of (TAE 10X or TBE 1x).  
Then 5 µL of molecular weight marker ladder was pipetted into the leftmost well. The 
ladder called IX was mostly used. These PCR molecular weight markers contained 
smaller DNA fragments than normal DNA markers and depend on the type of marker 
used, different ranges of size could be determined, being the number of base pairs 
directly proportional to the molecular weight (1 base pair=660 Daltons). Marker IX 
(Sigma) contained 11 DNA segments with increasing length starting from 72 bp while 
ending in 1353 bp, which were determined by computer analysis of DNA sequence. A 
mixture of 5µL samples and dye was loaded.  The electrophoresis box was set at 100 
volts 
 
8.4. Cas9 nuclease protein activity 
Once the image was acquired through the imaging device (ChemiDoc™ MP Imaging 
System) and saved in format tif., the intensity of the bands was quantified using 
ImageJ program.  
Following a tutorial (lukemiller.org, 2010), the tool, Gel Analyzer was used. Firstly, the 
RGB images were converted into gray scale image (8-bits), then different lanes with 
the deletion lanes were selected.  
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With Plot Lanes, the profile of each lane represents the relative density of the contents 
of the band over each lane. The bands arranged vertically (top to bottom) is localized 
from the left to the right in the plot. The higher and wider the peaks are, the darker and 
wider the bands are. As there was noise in the background of the blot, the values did 
not reach zero at the end, such that the profile remained open. In order to calculate the 
area (integral), a line was drawn manually while another line was used to separate the 
two bands as showed in Figure 20. Then by using Wand Tool, different areas 
representing different bands are selected and analyzed in term of area. Through Label 





in which a is the integral of the intensity of the band representing to the intact DNA 
segments, while b is the integral of the band corresponding to the corrected DNA 
segments.  




Figure 20. A) As an example, the plot obtained from the Plot Lanes of the PCR bands of dermis 
infected with HD Ad (1 and 3 are top bands while 2 and 4 are bottom bands). Lines were drawn to 





9. Toxicity assessment 
 
9.1. DAPI staining of keratinocytes 
Keratinocyte cultures were prepared following the same procedure described in the 
section 4.1., and transduced with HD or first generation adenoviral vectors. At day 6 of 
transduction, the cells were stained with DAPI (4′,6-diamidino-2-phenylindole) solution 
(10µg/mL). The membrane of dead cells tends to be porous and, therefore, more 
permeable to the staining than the living cells.  Based on this fluorescent stain, living 
cells could be differentiated from the dead cells through flow cytometry.  
Firstly, the cell suspension was centrifuged to be collected in form of pellet. Then the 
DAPI stock solution was diluted in staining buffer. 1 mL diluted volume was added to 
each cell sample, followed by incubation of 15 minutes at RT.  
 
9.2. FACS analysis 
The stained cell samples were analyzed by using FACS (fluorescence-activated cell 
sorting), a type of flow cytometer. The FACS device excites the sample by using a UV 
laser and detects the fluorescent light emitted by the DAPI inside cells responding the 
stimulation. Then it classifies the cells according to a set threshold of emission intensity, 
so that cells with intensity higher than this threshold are sorted as dead cells while 
those with lower intensity are considered living cells.  
 
 
Figure 21. A) How the stain emits fluorescent light in response to the light excitement. B) How the 
incident light is reflected. 
 
In the case of DAPI FACS, the fluorescent light was emitted from the nucleus. The 
forward scatter measured the size of cells by basing on the light diffraction around the 
cell. Cells with larger diameter have higher FSC intensity. Side scatter measurement 





1. Serial passage and HD adenoviral vector concentration  
The construct was designed in such a way that it expressed specific guides and Cas9 
protein inside the host cells to restore the COL7 production by eliminating the exon 80. 
For that purpose, once the 293Cre4 producer cells were transduced with Helper-
Dependent vectors and then with helper vectors, the virus production started. As a 
GFP sequence was connected to sgRNA-Cas9 with iRES between them, the cells that 
expressed this green fluorescence protein could be identified with microscope. The 
increase in intensity and number of fluorescent cells also showed that they produce 
more viral vectors during each passage illustrated in Figure 18. 
Living 293Cre4 cells were normally found attached to the bottom of culture plate while 
the dead ones were floating, such that the cell viability could also be checked through 
live cell imaging. The perfect passage to be amplified was defined as the culture with 
as much viral vectors as possible inside living Cre4 cells, that protected the viral 
particles from being discarded through cells collection and centrifugation.  
After amplification and collection through CsCl gradient ultracentrifugation to remove 
the toxic Helper vectors and other cellular components and to concentrate the vectors, 
Slide-A-Lyzer dialysis was carried out to complete the purification. A concentration of 
8x1012 particles/mL is obtained with vector size of 37kb, dilution factor of 20 and OD260 
of 0.374. 
This concentration is used to calculate the particles applied to the cell cultures in order 
to achieve certain MOI for later gene editing efficiency assessment. It does not always 
hold, that the higher the MOI is, the better results are obtained, because a large 
number of viral particles can be toxic.  
 
2. 2D culture gene editing 
Keratinocytes synthesize two third of collagen type VII in skin while fibroblasts produce 
the rest of this protein. Hence, they are the target cells for the therapy approaches. 
In order to test the ability of adenoviral vectors to transduce and the performance of 
Cas9 protein in term of mutated exon deletion, keratinocytes and fibroblasts carrying 
c.6527insC mutation were extracted from a patient to build simple 2D culture models. 
Once the cells were transduced with adenoviral HD vectors that carry Cas9 gene, the 
viruses infect the cells and introduce the viral genome into the nucleus. In this way, the 
cells produce Cas9 protein that can cut the DNA at the site recognized by guidance 
sequence. Therefore, the first step is to confirm that they actually entered into the host 
cells and made then synthesize the Cas9 through fluorescent light emission 





Figure 22.  Bright field image and green fluorescence of transduced patient keratinocytes with HD 
adenoviral vectors at different MOI at day 6. Magnification: 20X. 
 
 
Figure 23.  Segmented images are binary images. The background (white) is labeled with the lowest 
pixel value while the cells (black) are labeled with the height pixel value. 
In the bright field images in Figure 22, the cells were identif ied with keratinocytes 
morphology but neither the infection nor the production of gene editing proteins could 
be observed. Fluorescence emission of these cells provided this information. The viral 
genome delivering the cassette of Cas9 and GFP was incorporated into the host cell 
nucleus. Therefore, the presence of green fluorescence protein implies the successful 
infection and production of the nuclease. 
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The brightfield images segmentation task was more difficult due to the complex texture 
and varied intensities in the edges. From the original images, we could say that the 
confluency is similar at the three different MOI, while there was a clear difference in the 
fluorescence area and intensity according to Figure 23. As no nucleus staining was 
used, cell counting was not possible, so the transduction efficiency was based on the 
fluorescence area with respect to the confluency.  
 
 
Figure 24. Infection ratio calculated basing on the cell confluency and fluorescence area percentage 
with the program ImageJ.  
 
The area of fluorescent keratinocytes increases as the MOI rises as plotted in Figure 
24. From Figure 23, an increased intensity could also be observed. Focusing on bright 
field of the MOI 1000 showed in Figure 23, most of keratinocytes were attached to the 
bottom according to their morphology, which means they were alive, because dead 
keratinocytes were rounded and detached from the plate. However, this high infection 
did not cause a larger toxicity to the cells as keratinocytes confluency is similar to those 
infected at MOI 100 and 500. The toxicity was further discussed in another section with 
Figure 33 and 34. 
Even the fluorescence revealed the production of Cas9, the activity of this nuclease 
could not be determined, that is, the presence of Cas9 could not ensure the deletion of 
exon 80. Therefore, DNA analysis should be carried out in order to study the Cas9 
performance in term of exon 80 deletion.   
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2.2. PCR analysis 
DNA was extracted from infected keratinocytes and fibroblasts and underwent 
polymerase chain reaction (PCR). The small segment, amplified by PRC, exclusively 
contained introns 79 and 80, and exon 80 according to the primers R and F1, with a 
total length of 493 bp.  
   
Figure 25. The evaluation of the Cas9 activity on the patient keratinocytes (HK) and fibroblasts (FH) 
transduced with HD with increasing MOI. In the middle, the control (MOI 0) is found and represents the 
intact DNA fragment, while at the end, weight marker indicates that the DNA fragments were correctly 
amplified.  
There are two different molecular weight levels where the bands are localized. The 
DNA molecule suffering deletion has a shorter length (436 bp) such that it migrates 
faster and, therefore travelling longer distance, it is found in the lower level. The band 
derived from the culture without being infected serves as a negative control of the 
weight of uncut fragment and is retained in the higher level. 
Deletion of exon 80 was observed in the keratinocytes and fibroblasts transduced with 
MOI 100 and 1000, as the red narrows indicate. For both types of cells, the result was 
better as the MOI increases, that is, more viral particles (1000 particles) transducing a 
single cell. This is based on the fact that the top band intensity decreases and that of 
the bottom band increases.  
For the rest of cultures transduced with lower concentration, such as MOI 0.1, MOI 1 







3. 3D culture gene editing 
Organotypic culture is a powerful tool to mimic the skin due to its 3D structure and 
were used in many studies for Cas9 activity assessment. Thanks to the fibrin hydrogel 
embedding fibroblasts and the air-liquid interface, the keratinocytes could migrate and 
differentiate in response to the provided mechanical and chemical stimuli to form 
multilayered epithelium. The blister was formed (Figure 26.A) through needle that 
injected air into the hole created on the epidermis. Then the HD adenoviral particles 
were injected into the blister (Figure 26.B). This model mimics the blister in the RDEB 
patients, so we think it is a good model to assess the treatment. 
          
Figure 26. Blister formation and viral vectors injection. A hole is made on the epidermis layer and 
the air enters through needle and breaks the adhesion between epidermal and dermal layer. Then 




Figure 27. Fluorescence observation at day 4 of HD adenoviral vectors injection into the blister. There 
are two layers of organotypic culture, being the keratinocytes in the top epidermal layer and fibroblasts 
in the bottom dermal layer. Magnification: 20X. 
 
Both keratinocytes in epidermis and fibroblasts in dermis were infected. The difference 
between fluorescence distribution in Figure 27 is due to the different vertical planes 
during microscopic observation. 
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3.2. PCR analysis 
The PCR analysis obtained from amplified DNA extracted from the organotypic 
cultures is showed in Figure 28. It starts with the molecular weight marker, followed by 
the negative control (without transduction) and the positive control (corrected cells in 
2D culture). The control organotypic culture was not infected and, therefore, neither 
epidermis nor dermis presented deletion. In the infected cultures, the epidermis 
genome did not suffer edition, as there was no band at the position of bottom band of 
positive control which contains 50% cells with exon deletion. 
 
 
Figure 28. Evaluation of the performance of sgRNA-Cas9 on the organotypic culture having blister 
injected with HD adenoviral vectors. C- is negative control, C+ is control with 50% deletion, E 
stands for epidermis and D for dermis. 
 
A blister formation separating the epidermal and dermal layer could cause an abrupt 
damage on the basal layer of keratinocytes. Without the nutrients and signals provided 
by the dermis, the keratinocytes could not proliferate. Even the keratinocytes were 
infected by the viral vectors, they could not be edited because they did not proliferate.  
This also explained why fluorescence was observed in keratinocytes (epidermis) at 4 
days after virus injection into blister (Figure 27) but no correction was achieved (Figure 
28). In contrast, the fibroblasts were more independent from the keratinocytes for 






4. Graft in vivo gene editing  
The graft take rate consisted of 8 weeks, which were necessary for the regenerative 
skin to become mature and completely taken into the mouse skin. During this take 
process, keratinocytes of the organotypic differentiated and acquires the squamous 
stratified organization. Then the vacuum device caused the separation of the epidermis 
from the dermis to form a small blister (Figure 29), into which the viral vectors were 
injected. Several days later, the mice were observed through fluorescence microscopy 
in term of in vivo infection (Figure 30). 
        




Figure 30. Fluorescence images of three implanted skin grafts. HD adenoviral vectors were injected 
into the blister made by the vacuum device. A) Observation at day 10 of infection. B) Observation at day 
9 of infection. C) Observation at day 7 of infection. 
 
In the first graft (Figure 32, A), there is no vivid green fluorescent light, the weak green 
light might be the autofluorescence of the cells. In the second graft (B), an area at the 
boundary of implanted skin equivalents could be clearly identified with more intensive 
green fluorescence. The last graft (C) had the largest area with fluorescence, 
especially at the whole boundary.  
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5. Cytotoxicity of HD and first generation adenoviral vectors 
Previous researches in the laboratory with first generation adenoviral vectors showed a 
high toxicity in vitro assessment.  
Our hypothesis was that HD vectors would be less toxic because they lacked almost all 
viral genome, the expression of which could be toxic for transduced cells. In order to 
confirm that, these two different generations of adenovirus were applied to infect 
keratinocytes cultures at different MOI under same conditions. At day 6 of infection, 
they were collected for FACS analysis. 
 
 
Figure 31. Toxicity assessment of two types of adenoviral vector on patient keratinocytes at day 6 
of infection. Dot plots represent the fluorescence intensity of DAPI (vertical axis) against the FSC area 
(horizontal axis).  
 
The FSC area of the plots in Figure 31 is the forward scatter intensity, which is 
proportional to the cell diameter.  The intensity of DAPI is proportional to the amount of 
DAPI stain taken by the cells. As dead cells have more permeable cell membrane, they 
express blue staining with higher intensity. Therefore, those cells expressing DAPI 
intensity higher than the threshold are classified as dead cells (DAPI+ %). The 




Figure 32. Numerical representation of DAPI positive cell percentage obtained from Figure 31. The 
plain columns belong to the HD (gray) and first generation adenoviral vectors (black), while the stripe 
column is the difference between first and HD vector cytotoxicity. 
 
In both the culture infected with MOI 100 and MOI 500, the HD and the first generation 
vectors have similar DAPI%, being that of HD one even slightly higher than the first 
generation (Figure 32). Nevertheless, the fluorescence increased dramatically in the 
case of cells infected with first generation vectors at MOI 1000. Meanwhile, the DAPI 
fluorescence of those infected with HD vectors slightly decreased, showing that HD 
vectors are less toxic. Moreover, PCR analysis results from HD and first generation 
infecting keratinocytes in 2D culture are compared. With multiplicity of infection lower 
than 3000 of first generation vectors, no deletion on the exon 80 was observed, as 






The genome editing tool used in our study is the sgRNA-Cas9 complex, the cassette of 
which is delivered by helper-dependent adenoviral vectors. Even the Cas9 derived 
from Streptococcus pyogenes is the most commonly used type, the Staphylococcus 
aureus was chosen because of a more specific PAM and smaller molecular weight, 
which could result in less off-target activity of Cas9 protein. 
After the double-strand break (DSB) caused by Cas9 protein, DNA repair through 
NHEJ occurred due to the lack of homologous template.  As Cas9 could cause both 
blunt and sticky ends, being the NHEJ less accurate in blunt cuts. This is because 
during the repair at the endpoints, known deoxyribonucleotides could be added to the 
sticky cut ends, while random ones would be added to the blunt ends. But in both 
cases, small insertions and deletions (indels) could be introduced. It is worth noting 
that the two DSB occurred in the intron 79 and intron 80 in the gene COL7A1, because 
the two guide RNA were designed to target the exon 80. Thanks to the collagen 
specifically repeated organization, the normal function of this protein will be restored if 
the reading frame has been corrected. As there are only three possible reading frames 
(because 3 units forming a codon), at least one third of cells with E80 deletion would 
synthesize normal collagen VII.  
But the delivery system determines the number of cells that can be modified, they way 
we introduce the therapeutic RNA or DNA into the cells is also crucial. Previous studied 
used different systems to carry sgRNA-Cas9 complex. One method consisted of 
delivering the sgRNA-Cas9 in form of ribonucleoprotein into the keratinocytes through 
electroporation. The other one is the first generation adenoviral vectors carrying the 
sgRNA-Cas9 cassettes within the double-strand viral genome. This two studies are 
compared with the HD adenoviral vectors in this chapter. 
But firstly, the difference in the results obtained from 2D and 3D cultures transduced 
with the HD vectors, is discussed. 
 
1. 2D versus 3D models 
Due to different culture organization, the performance of viral vectors also varied. In 2D 
culture, the surface of cells in small suspension is more exposed to viral particles, 
favoring the absorption and interaction between virus fiber and receptors on cell 
membrane. However, there are more barriers, even with the in vitro organotypic culture. 
Since the serotype5 adenovirus was discovered in human lung epithelial cells, it was 
expected to have a higher affinity to epithelial cells including keratinocytes. This is 
supported by the finding that in 2D culture at a lower MOI (100), the percentage of 
corrected keratinocytes was higher than that of corrected fibroblasts. At MOI 1000, 
high percentage of correction was obtained from both cell types, which is 86.1% and 
95.9% for keratinocytes and fibroblasts respectively (Figure 25). 
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In the case of in vitro organotypic infected with HD vectors, only cells in the dermis 
layer suffered correction. Even part of epidermis was infected according to 
fluorescence observation (Figure27), there was no deletion in keratinocytes that were 
separated from the dermis due to blister formation and did not proliferate (Figure 28). 
Although the keratinocytes are the main collagen VII producer cells, fibroblasts also 
contribute to the epidermal and dermal adhesion by synthesizing one third of collagen 
VII. 
According to a study of fibroblast cell therapy for RDEB, the intradermal injection of 
wild type fibroblasts into Collagen VII knockout mouse models increased the amount of 
this protein in dermal-epidermal junction 4- to 5-fold (Kern JS, 2009). Although the 
synthesis of collagen VII lasted less than 4 weeks, the already produced protein could 
maintain the adhesion between epidermis and dermis, which was able to resist 
mechanical forces.  
Not only in mice model, the RDEB patients were treated with allogeneic fibroblasts 
from one of their parents through intradermal injection (TracyWong, 2008). Later 
assessment found an increased collagen VII and anchoring fibrils synthesis from 2 
weeks to 3 months after treatment. 
Additionally, a research found that the Collagen VII half-life (the time after which the 
amount of the protein decreases by 50%) in murine skin was about one month, which 
is considerably long compared with other collagen types (Tobias Ku ̈hl, 2016). The 
researchers also found that single collagen VII half-life is several times shorter than 
that of anchoring fibril. It seems that once these extracellular proteins are secreted and 
integrated into the DEJ, where they form the anchoring fibrils through cross-linking by 
transglutaminase. Hence, the fibril is more stable than single collagen protein, so that it 
is also more resistant to degradation. 
The successful synthesis of Collagen VII through normal fibroblasts injection and the 
high stability of both protein and the resulting anchoring fibril were achieved. Based on 
this, we expect that during in vivo gene editing, the infected fibroblasts with E80 
deletion and with restored COL7A1 expression could synthesize enough amount of 
collagen to form the anchoring fibrils and support the keratinocytes reepithelialization in 









2. Viral versus non-viral delivery system 
The previous study (Jose Bonafont, 2019) consisted in delivery sgRNA-guided Cas9 
nucleases through nucleofection into the RDEB keratinocytes as a novel delivery 
system, because it is the nuclease itself being delivered. There were four different 
sgRNA pairs associated with the ribonuleoprotein complexes in order to test which pair 
could yield the best result.  
 
 
Figure 33. PCR analysis of DNA from keratinocytes treated with ribonucleoprotein complexes. The 
deletion ratios were obtained through densitometry. Two nucleofection conditions were tested and 
referred as A and B. P1 represents the unedited keratinocytes from a patient (Jose Bonafont, 2019). 
 
From the results obtained through PCR analysis (Figure 34), keratinocytes treated with 
sg2+sg3-Cas9 nucleases have the highest deletion percentage (61.9% and 66.5%). It 
is important to recall that the deletion percentage in keratinocytes infected with HD 
vectors at MOI 1000 was 86.1% showed in Figure 25. In both delivery systems, the 
ratio of edited alleles is higher than 50%. 
Furthermore, the immunofluorescence analysis with a specific anti-C7 antibody 
showed the expression of Collagen VII in 81% RDEB keratinocytes treated with 
sg2+sg3-Cas9 nucleases. The successful long-term engraftment was also achieved by 
using polyclonal populations of RDEB keratinocytes with E80 deletion, which suggests 
that epidermal stem cells were edited.  
All these compromising results obtained in this ex vivo correction of RDEB 
keratinocytes encouraged the use of HD adenoviral vectors carrying sgRNA-Cas9 
cassette for in vivo gene editing therapy. 
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3. In vivo versus ex vivo gene therapy 
Unlike the internal organs, skin is exposed to air and can be easily accessed and 
treated with corrected cells transplantation. Therefore, the most commonly used 
method for skin is ex vivo therapy, with a vast number of studies proving the high 
delivery efficiency. However, this approach starts from taking the patient biopsy, 
followed by extraction of specific cells, correction, amplification, differentiation and, 
finally, transplantation. The whole process is time-consuming. In contrast, in vivo 
therapy is fast, because it simply consists of injection of vectors carrying the transgene, 
without any cell manipulation.  
However, these vectors find much more physiological barriers when they are injected 
directly than when they are applied to cell suspension, so that the uptake efficiency is 
relatively lower. Another difficulty is the immune response caused by viral vectors. 
The first-generation vectors were not considered as a good candidate for the in vivo 
gene therapy for the following reasons. These viruses are also replication-deficient 
vectors, due to the E1 regions removal to prevent E2 gene expression, and also need 
to be produced in complementing human cell lines (293 cells) that provided the genes 
necessary for replication. However, after gene editing, the viral genome still remained 
inside the host cells and its expression resulted in viral proteins that are toxic. In 
addition to the high toxicity, the deletion in keratinocytes infected with these vectors 
was observed from MOI equal or higher than 3000 (Figure 34). Therefore, 30 times 
more first generation viral particles would be needed to achieve a similar correction 
ratio in HD viral particles, as this type achieved deletion with MOI 100 (Figure 25). 
 
 
Figure 34. PCR analysis of DNA from keratinocytes infected with first generation adenoviruses with 
different MOI (previous result in the research center). 
  
Furthermore, the synthesized viral proteins would be exposed on the transduced cell 
membrane and, in this case, would induce immune response by attracting T cells and 
natural killers. Subsequently, the target cells would be destroyed. In contrast, the 
genome of HD is mainly composed of stuffer sequence that do not result in protein. In 






- High concentration of Helper-Dependent adenoviral vectors was obtained after serial 
passage, amplification and ultracentrifugation 
 
- In 2D culture model, exon 80 deletion in COL7A1 gene occurred at MOI 500 and MOI 
1000, being the last with that yield 86% and 96% deletion in keratinocytes and 
fibroblasts respectively 
 
- In the organotypic culture consisting of fibroblasts embedded in fibrin gel and 
keratinocytes seeded on the top, the blister was formed to mimic the situation of RDEB 
patients, and then treated with HD vectors. According to the PCR analysis, exon 80 
deletion was only observed in fibroblasts  
 
- More realistic models of RDEB patients skin were created through skin equivalent 
maturation once transplanted in immunodeficient mice, while the blister was formed 
with vacuum device. The presence of green fluorescence from the graft on the mouse 
proved that cells in the blister were successfully infected  
 
- The toxicity analysis demonstrated our hypothesis that HD vectors would be less toxic 
than the first generation vectors due to the lack of almost all viral genome. This was 
possible thanks to the presence of helper adenoviruses during production and 
amplification. In this way, after the genetic modification, no viral protein will be 
produced inside the host cells 
 
- The MOI needed to cause the exon 80 deletion is reduced from MOI 3000 (first 
generation adenoviruses) to MOI 100 with HD, that is less number of viral particles can 
be used to achieve the same therapeutic effect, which could further decrease the 
toxicity and immune response 
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CHALLENGES AND FUTURE WORK 
 
- As the promoter is PGK, which is expressed in almost all human cell types, the gene 
editing would be carried out in any human cell. During in vivo viral vectors 
administration, cells different to keratinocytes and fibroblasts could be infected and 
suffer exon 80 skipping. Even they do not actively produce collagen VII, genetic 
modification can somehow threaten the DNA molecules. The next step is to produce a 
HD adenoviral vector that only allows the Cas9 expression in a single cell type. This 
can be achieved by using, for instance, the promoter that regulates keratin 5, which is 
only expressed in keratinocytes.  
 
- A deeper understanding on the kinetics of Cas9-sgRNA complex and the stability of the 
transgene in different conditions and cell types can improve the nuclease activity and 
DNA correction in both in vitro and in vivo approaches 
 
- Inactivation of Cas9 gene remaining inside the cells can prevent its off-target 
activity. There is a newly developed method that consists of cleaving the viral own 
genome encoding Cas9 by the Cas9 itself. Cas9 cuts the desired site in the DNA 
molecules of the host cells following one of the sgRNA, and also cuts the Cas9 
gene of viral genome under the direction of the other sgRNA (Donna J.Palmer, 
2019) 
 
- The homologous recombination can be considered for DSB repair with the 
introduction of a template into the viral vector design. In this method, higher 
percentage of corrected cells could express the COL7A1 with the correct reading 
frame but without indels that could affect intron-splicing-signals. 
 
 
- Another limitation is that the immune response. As serotype 5 adenoviruses are 
commonly causes of respiratory infections, many people have developed 
antibodies against the proteins forming adenoviral capsid. This is a problem in vivo 
gene therapy, where the viral vectors are directly injected into the patient body. 
Recently studies show that the serotype 5 capsid can be replaced by the capsid of 
chimpanzee serotype 35 adenovirus to avoid immune response and acute 





REGULATORY FRAMEWORK AND SOCIECONMIC IMPACT 
 
1. EU regulations 
The final products resulting from gene therapy, along with those from tissue 
engineering and cell therapy, are considered as part of the Advanced Therapy 
Medicinal Products (ATMPs). Due to the biological components, these products are 
highly variable, patient-dependent and concerned about the following aspects: safety 
implications, ethical aspects, lack of data about therapeutic effects and low stability.  
Hence, they need to be controlled by ATMP Regulation (Regulation (EC) 1394/2007). 
This regulation, agreed by several EU institutions, specifies many requirements, such 
as cell sources, pre-clinical development, risk analysis, manufacturing process and 
risk-based approach, allowing the traceability of each production step. The ATMPs 
must be carried out in an authorized center following good manufacturing practices 
(GMP). This continuous control aims at avoiding any error during production to ensure 
the safety and efficiency of the final medicinal product. Another element of this 
regulation consisting of registry and commercialization, allows free movement of these 
medicinal products within Europe and facilitates the European companies to access 
into this new field.  
 
 
Figure 35. Advanced Therapies Medicinal Products (Celis, 2018). 
 
The genetically modified organisms (GMO) like recombinant viral vectors and the 
corrected cells yielding more complex tissues must obey the Directive 2001/18/EC or 
Directive 2009/41/EC during clinical trials.  
As the in vivo approach of correcting the COL7A1 gene with adenoviral vectors is still 
in the experimental stage and need further research and improvement, the regulation 
chapters of GMP were not applied to this project. Nevertheless, it is important to have 
them in mind and to follow the good practice in cell culture and molecular laboratories 
in term of the materials, the experiment procedure and the waste management. In this 




In addition to the product quality that ensures the patient safety, the safety of the 
researchers constantly exposed to biological agents is also an important issue. In the 
case of inappropriate manipulation, these agents can be source of contamination and 
cause unexpected harm. Since genetically modified microorganisms are also 
considered as biological agents, their contained use regulation is linked to those 
applied to the Directive 2000/54/EC, the legislation on biosafety. The virus production 
and keratinocytes, fibroblasts and organotypic cultures were carried out in Keratolab in 
CIEMAT, which is a laboratory specialized in primary culture of skin cells. Equipment 
like the laminar flow hood of biosecurity level II forms a barrier between the cell 
cultures and the personal.  
The skin equivalent transplantation and later fluorescence observation of in vivo HD 
adenoviral vectors performance was carried out in the CIEMAT Laboratory Animals 
Facility, which provides services like breeding of immunodeficient, transgenic or 
irradiated mice models. The animals are kept in a pathogen-free conditions while their 
manipulations were done obeying the regulations defined in European Convention 123, 
use and protection of vertebrate animals in experimentation and other scientific 
purposes.  
 
2. Social responsibility 
A rare disease is considered to be carried out by no more than 5 in every 10.000 
people. According to estimations, there is a range of 5000 to 8000 genetic rare 
diseases, which is supposed to affect 6% of European population. CIBERER points out 
that there are around 3 million Spanish people suffering a rare disease, which affects 
not only children, but can also arise during an adult’s life. Compared with this large 
number of patients, there is however few efficient commercial treatments for these 
diseases. Due to their high specificity and variability, large pharmaceutic companies 
are not interested in offering treatment for rare diseases. This responsibility has always 
been assumed by public research centers, among which CIEMAT plays a great role 












3. Project cost 
Experimental Materials 
Company Material  Cost/unit (€) Units Total (€) 
Integrated DNA Technologies crRNA1 2nmol 72.00 0.2 14.40 
 crRNA2 2nmol 72.00 0.2 14.40 
 tracrRNA 5nmol 72.00 0.5 36.00 
 Cas9 nuclease 100µg 195.00 0.03 5.85 
GlutaMAX, Gibco 
DMEM 500mL 27.00 20 540.00 
 F12 500mL 32.00 4 128.00 
HyCloneTM FBS 50mL 81.00 1 81.00 
 Bovine Calf Serum 500mL 64.00 2 128.00 
Sigma-Aldrich TRYPSIN 100mL 15.00 1 15.00 
 PBS 500 17.00 2 34.00 
 Matrigel 1mL 139.00 0.5 69.50 
 Thrombin 10 mg 139.00 0.2 27.80 
 cholera toxin 10mL 301.00 0.2 60.20 
 Ascorbic acid 10mL 122.00 0.2 24.40 
 insulin 10mL 111.00 0.2 22.20 
 
antibiotics 100µL 340.00 0.1 34.00 
Thermo Scientific TAE 50x 1L 34.00 0.1 3.40 
Amchafibrin, FidesEcofarm tranexamic acid 10mL 315.00 0.2 63.00 





Company Material  Cost/unit (€) Units Total (€) 
Fischer Scientific Petri dish 150mm 500u 390.00 0.2 78.00 
 Petri dish 60mm 500u 390.00 0.2 78.00 
 Petri dish 35mm 500u 428 0.1 42.80 
 Plate 6 wells 50u 132 0.1 13.20 
 Transwell 60u 305.00 0.5 152.50 
 
Stripette 1.5mL 500u 45.00 0.2 9.00 
 Stripette 2mL 200u 67.00 1 67.00 
 Stripette 5mL 200u 67.00 1 67.00 
 Stripette 10mL 200u 67.00 0.5 33.50 
 Stripette 25mL 200u 67.00 0.5 33.50 
   Total 574.50 
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